Journey Clinical

Journey Clinical is a technology company.

Active

Updated: Dec 10, 2025 ·

Recent News & Mentions

Jan 1, 2023FundingJourney Clinical - Series A Sep 1, 2021FundingJourney Clinical - Seed Jul 1, 2021FundingJourney Clinical - Seed Jan 1, 2021FundingJourney Clinical - Pre-seed

Financial History

Journey Clinical has raised $12.4M across 4 funding rounds. Most recently, it raised $9.0M Series A in January 2023.

Total Raised

$12.4M

Valuation

N/A

Funding Rounds Raised

Date	Round	Other Investors
Jan 1, 2023	$9.0M Series A	Beckley Waves, Equal Ventures, Jenny Fielding, Scott Hartley, Fifty Years, Mystic Ventures, PsyMed Ventures, Sozo Ventures, Union Square Ventures, Edvard Engesæth, Jett McCandless, Will Szczerbiak
Sep 1, 2021	$3.0M Seed	2xN, Alumni Ventures, Beckley Waves, Fifty Years, Founders Fund, Granite Asia, Kleiner Perkins, Mystic Ventures, PsyMed Ventures, Union Square Ventures, Dylan Field, Edvard Engesæth
Jul 1, 2021	$250K Seed	Endeavor Venture Funds, Future Ventures, Negev Capital, PsyMed Ventures, What If Ventures, Akshay Sriprasad
Jan 1, 2021	$150K Pre-seed	Beckley Waves, Endeavor Venture Funds, Future Ventures, Negev Capital, PsyMed Ventures, What If Ventures, Akshay Sriprasad

Financial History

Journey Clinical has raised $12.4M across 4 funding rounds.

Total Raised

$12.4M

Valuation

N/A

Deep Dive

# Journey Clinical: High-Level Overview

Journey Clinical is a healthtech platform that empowers licensed psychotherapists to deliver psychedelic-assisted psychotherapy (PAP) to their patients.[1][2] The company operates as a B2B marketplace and decentralized clinic network, handling the medical, administrative, and clinical infrastructure that traditionally barriers therapists from offering these treatments.[1] Journey Clinical serves two primary constituencies: licensed mental health professionals seeking to expand their practice offerings, and patients with treatment-resistant depression, anxiety, and other mental health conditions who have not responded to traditional pharmacological approaches.[1][2]

The company addresses a critical gap in mental healthcare access. While psychedelic-assisted therapies show significant clinical promise—Journey Clinical reports that 87% of ketamine-assisted psychotherapy (KAP) patients report improvement in depression and anxiety scores after just two medical visits—these treatments remain largely inaccessible to most Americans.[3] Journey Clinical removes barriers by providing therapists with training, peer support, regulatory compliance frameworks, and an in-house medical team that handles prescriptions, screening, and ongoing psychiatric medication management.[1][2] Since launching approximately one year before its featured interview, the platform has attracted over 700 providers who have treated more than 1,000 patients, positioning it as the largest network of psychedelic-assisted psychotherapy providers in the US.[1][2]

# Origin Story

Journey Clinical was founded by Jonathan Sabbagh and Myriam Barthes, with Sabbagh serving as co-founder and the company's CEO.[2] The founding story is deeply personal: Sabbagh experienced his own mental health transformation through psychedelic therapies, gaining relief from chronic burnout and PTSD.[2] This personal breakthrough catalyzed a broader mission—recognizing that millions of Americans living with mental illness lacked safe, reliable, and affordable access to these powerful treatments, the founders set out to democratize psychedelic-assisted care by building infrastructure that would enable community-based therapists to deliver these modalities responsibly.[2]

The company's early traction reflects strong market demand and investor confidence. Journey Clinical has raised $11.5 million across two funding rounds, with the most recent round bringing in $8.5 million.[4] The company's rapid provider adoption—700+ therapists in its first year—demonstrates both the appetite among mental health professionals to expand their treatment offerings and the effectiveness of Journey Clinical's platform in reducing the operational and regulatory friction that previously made psychedelic-assisted therapy inaccessible to most practitioners.

# Core Differentiators

Collaborative Care Model: Unlike traditional clinic-based psychedelic therapy programs, Journey Clinical positions licensed therapists as the primary treatment providers, with an in-house medical team (led by Dr. Kyle Lapidus MD PhD) providing supporting psychiatric care, prescriptions, and medication management.[2][3] This model leverages the therapeutic relationship therapists already have with their patients while removing the medical and administrative burden.

Largest Provider Network: Journey Clinical operates the largest network of licensed psychedelic-assisted psychotherapy providers in the US, creating network effects that benefit both therapists (access to peer mentorship, consultation, workshops, and community support) and patients (choice and accessibility).[2][7]

Turnkey Platform: The company provides a complete infrastructure stack—eligibility screening, prescription management, treatment planning, outcome monitoring, and ongoing psychiatric care—allowing therapists to focus on the therapeutic work rather than regulatory compliance and medical logistics.[1][3]

Proven Clinical Outcomes: The 87% improvement rate in depression and anxiety clinical scores after two medical visits provides concrete evidence of efficacy, differentiating Journey Clinical from competitors and building trust with both providers and patients.[3]

Community-Centric Approach: Beyond the platform itself, Journey Clinical has built a robust community ecosystem including peer mentorship, an active member forum, workshops, and networking events that support therapists in delivering high-quality care.[6][7]

# Role in the Broader Tech Landscape

Journey Clinical sits at the intersection of three powerful trends reshaping healthcare and mental health treatment. First, it capitalizes on the growing clinical validation and regulatory acceptance of psychedelic-assisted therapies, with ketamine already approved for medical use and other psychedelics advancing through FDA trials.[2] Second, it exemplifies the broader shift toward decentralized, community-based healthcare delivery—moving away from centralized clinics toward distributed networks of independent providers supported by digital infrastructure.[1] Third, the company addresses the mental health crisis with a technology-enabled solution, tapping into the massive market opportunity created by treatment-resistant depression and anxiety affecting millions of Americans.

The timing is particularly significant. As traditional psychiatric medications (SSRIs and other first-line treatments) prove insufficient for a substantial portion of patients, psychedelic-assisted therapy represents a genuine clinical breakthrough.[3] Journey Clinical's platform removes the last major barrier to scale: the lack of accessible, compliant infrastructure for community therapists. By enabling the decentralization of psychedelic-assisted care, Journey Clinical is not just building a company—it is reshaping how frontier mental health treatments reach patients, influencing the broader healthcare ecosystem toward more accessible, therapist-centered care models.

# Quick Take & Future Outlook

Journey Clinical is positioned at an inflection point. The company has validated product-market fit through rapid provider adoption and strong clinical outcomes, but the real opportunity lies ahead: as additional psychedelic modalities receive FDA approval beyond ketamine, Journey Clinical's platform and provider network become increasingly valuable.[2] The company's expansion into comprehensive psychiatric medication management signals a vision of becoming a full-stack mental health platform for community therapists, not just a psychedelic-specific tool.

The key question shaping Journey Clinical's trajectory is whether it can maintain its position as the dominant provider network while scaling to serve the millions of Americans with treatment-resistant mental illness. Success requires balancing rapid growth with clinical rigor, ensuring that as the network expands, quality and outcomes remain exceptional. If Journey Clinical executes effectively, it could fundamentally reshape how Americans access transformative mental health treatments—moving from a model where psychedelic-assisted therapy is a rare, expensive specialty to one where it is an accessible option within community-based care.

Sources

Frequently Asked Questions

How much funding has Journey Clinical raised?

Journey Clinical has raised $12.4M in total across 4 funding rounds.

Who are Journey Clinical's investors?

Journey Clinical's investors include Beckley Waves, Equal Ventures, Jenny Fielding, Scott Hartley, Fifty Years, Mystic Ventures, PsyMed Ventures, Sozo Ventures, Union Square Ventures, Edvard Engesæth, Jett McCandless, Will Szczerbiak.